- Conditions
- Hepatitis C, Non-Alcoholic Fatty Liver Disease
- Interventions
- Placebo, Silymarin
- Drug
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 514
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg, SP-304 9.0 mg, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 14
- States / cities
- Mesa, Arizona • Tucson, Arizona • Anaheim, California + 11 more
- Conditions
- Hepatitis C
- Interventions
- PSI-352938, PSI-7977
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Obinutuzumab, ABBV-453
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Duarte, California • Irvine, California • Billings, Montana + 3 more
- Conditions
- Asthma
- Interventions
- Benralizumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 23
- States / cities
- Flagstaff, Arizona • Los Angeles, California • Aurora, Colorado + 20 more
- Conditions
- Heart Failure
- Interventions
- Finerenone (BAY94-8862), Placebo, Inspra (eplerenone)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,066 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more
- Conditions
- Anemia, End Stage Renal Disease
- Interventions
- AKB-6548
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 16
- States / cities
- El Granada, California • Long Beach, California • San Dimas, California + 13 more
- Conditions
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Oral Azacitidine, Positron Emission Tomography, Prednisone, Questionnaire Administration, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 75 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 176
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 136 more
- Conditions
- Chronic Migraine
- Interventions
- Atogepant, Placebo for Atogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 32
- States / cities
- Huntsville, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 29 more
- Conditions
- Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myelogenous Leukemia (AML)
- Interventions
- Subcutaneous (SC) Azacitidine, Oral Azacitidine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 18
- States / cities
- Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 15 more
- Conditions
- Muckle Wells Syndrome, Autoinflammatory, Behcet's Disease
- Interventions
- XOMA 052
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Anemia, Renal Insufficiency, Chronic
- Interventions
- Molidustat (BAY85-3934), Epoetin alfa/beta
- Drug · Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 23
- States / cities
- Azusa, California • Long Beach, California • Lynwood, California + 16 more
- Conditions
- Chronic Venous Leg Ulcers
- Interventions
- EPA+DHA, placebo
- Dietary Supplement · Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chronic Pain
- Interventions
- Not listed
- Lead sponsor
- Asokumar Buvanendran
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- Fingolimod, Placebo Comparator
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 12
- States / cities
- Orange, California • Miami, Florida • St. Petersburg, Florida + 9 more
- Conditions
- Thyroid Diseases, Chronic Periodontitis
- Interventions
- NO intervention, patient records review only
- Other
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 4,965 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Heart Failure
- Interventions
- Empagliflozin, Placebo to Empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Orange, California • Torrance, California + 25 more
- Conditions
- Chronic Stable Plaque Psoriasis
- Interventions
- Placebo, 400 mg (200 mg BID), 300 mg (150 mg BID)
- Drug
- Lead sponsor
- Innovation Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 34
- States / cities
- Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 27 more
- Conditions
- Healthy, Inflammation, Mouth Disease, Pain
- Interventions
- Not listed
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- Not listed
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Heart Failure
- Interventions
- Polysaccharide Iron Complex 150 mg, Placebo (for Polysaccharide Iron Complex)
- Drug
- Lead sponsor
- Adrian Hernandez
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 17
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 8 more
- Conditions
- Leukemia
- Interventions
- Polyphenon E
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Obstructive Pulmonary Function, Restrictive Pulmonary Function
- Interventions
- single dose (100 mg) of ASA, single dose (162 mg) of non-enteric-coated chewable aspirin tablets
- Drug
- Lead sponsor
- Vectura, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Winter Park, Florida • Baltimore, Maryland + 1 more
- Conditions
- Chronic Myelogenous Leukemia, Hematologic Malignancies
- Interventions
- Ponatinib
- Drug
- Lead sponsor
- Ariad Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 5
- States / cities
- San Francisco, California • Ann Arbor, Michigan • Portland, Oregon + 2 more
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- penclomedine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin